![](https://news.europawire.eu/wp-content/uploads/2021/08/Roche-FACADE-144x144.jpg)
(IN BRIEF) Roche has announced promising results from the Phase III INAVO120 study, which evaluated inavolisib in combination with palbociclib (Ibrance®) and fulvestrant as a first-line treatment for individuals with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced, or metastatic … Read the full press release